Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer.
Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol. 2008 Dec; 111(3):530-2.
View in:
PubMed
subject areas
Aged, 80 and over
Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Ascites
Bevacizumab
Female
Humans
Infusions, Parenteral
Ovarian Neoplasms
Palliative Care
Paracentesis
authors with profiles
Chad A Hamilton